Good news - Tarcine BioMed, a subsidiary of BAHEAL Pharmaceutical Group, has successfully passed the review for high-tech enterprise status
发布时间：2024-12-20 浏览次数：410次 作者：
Recently, in accordance with the relevant provisions of the "Administrative Measures for the Recognition of High-tech Enterprises" and the "Guidelines for the Administration of High-tech Enterprise Recognition", Tarcine BioMed (Beijing) Inc., a subsidiary of BAHEAL Pharmaceutical Group, successfully passed the qualification review for high-tech enterprises after guidance and review by experts at all levels. It once again obtained the "High-tech Enterprise Certificate" jointly issued by the Beijing Municipal Science and Technology Commission, the Municipal Finance Bureau, and the Municipal Water Affairs Bureau. Certificate number: GR202411001646.
Tarcine BioMed is located in Zhongguancun Life Science Park and is affiliated with Baheal Pharmaceutical Group. Baheal Pharmaceutical Group is a health industry group driven by technological innovation. Based on industrialization capabilities, with asset appreciation as the core and innovation incubation as the feature, the group has now established an industrial pattern featuring the incubation of medical innovation achievements, manufacturing, and collaborative development of commercialization, effectively optimizing medical scenarios through technological innovation.
As a research and technology transformation platform under Baheal Pharmaceutical Group, Tarcine BioMed is primarily engaged in the development and industrialization of early warning and early diagnosis technologies for major human diseases. With a full industrial chain covering research and development, production, and sales, it has formed an early diagnosis technology application platform for major human diseases, based on research and development capabilities, centered on early diagnosis, and characterized by international collaboration. It provides sensitive and specific diagnostic reagent products and services for human health. Tarcine BioMed has always adhered to product innovation and currently holds 35 relevant invention patents and 29 product registration certificates.
The successful review of Tarcine BioMed as a "high-tech enterprise" fully recognizes the progress Tarcine BioMed has made in research and development, production, and management in recent years. In the future, Tarcine BioMed will continue to strive to enhance its technological competitiveness and contribute more to the high-quality development of the healthcare industry.
